237 related articles for article (PubMed ID: 20937436)
1. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.
Douglas AD; de Cassan SC; Dicks MD; Gilbert SC; Hill AV; Draper SJ
Vaccine; 2010 Oct; 28(44):7167-78. PubMed ID: 20937436
[TBL] [Abstract][Full Text] [Related]
2. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
4. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Collins KA; Ewer KJ; Spencer AJ; Williams AR; Halstead FD; Moretz SE; Miura K; Epp C; Dicks MD; Poulton ID; Lawrie AM; Berrie E; Moyle S; Long CA; Colloca S; Cortese R; Gilbert SC; Nicosia A; Hill AV; Draper SJ
Mol Ther; 2011 Dec; 19(12):2269-76. PubMed ID: 21862998
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.
Kumar S; Jones TR; Oakley MS; Zheng H; Kuppusamy SP; Taye A; Krieg AM; Stowers AW; Kaslow DC; Hoffman SL
Infect Immun; 2004 Feb; 72(2):949-57. PubMed ID: 14742540
[TBL] [Abstract][Full Text] [Related]
6. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
[TBL] [Abstract][Full Text] [Related]
7. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
[TBL] [Abstract][Full Text] [Related]
8. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
Biswas S; Choudhary P; Elias SC; Miura K; Milne KH; de Cassan SC; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Osier FH; Hodgson SH; Duncan CJ; O'Hara GA; Long CA; Hill AV; Draper SJ
PLoS One; 2014; 9(9):e107903. PubMed ID: 25254500
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
Genton B; Al-Yaman F; Anders R; Saul A; Brown G; Pye D; Irving DO; Briggs WR; Mai A; Ginny M; Adiguma T; Rare L; Giddy A; Reber-Liske R; Stuerchler D; Alpers MP
Vaccine; 2000 May; 18(23):2504-11. PubMed ID: 10775784
[TBL] [Abstract][Full Text] [Related]
10. Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.
Forbes EK; Biswas S; Collins KA; Gilbert SC; Hill AV; Draper SJ
J Immunol; 2011 Oct; 187(7):3738-50. PubMed ID: 21876036
[TBL] [Abstract][Full Text] [Related]
11. Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.
Pusic K; Xu H; Stridiron A; Aguilar Z; Wang A; Hui G
Vaccine; 2011 Nov; 29(48):8898-908. PubMed ID: 21963870
[TBL] [Abstract][Full Text] [Related]
12. The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus.
de Cassan SC; Forbes EK; Douglas AD; Milicic A; Singh B; Gupta P; Chauhan VS; Chitnis CE; Gilbert SC; Hill AV; Draper SJ
J Immunol; 2011 Sep; 187(5):2602-16. PubMed ID: 21813775
[TBL] [Abstract][Full Text] [Related]
13. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
[TBL] [Abstract][Full Text] [Related]
14. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates.
Padte NN; Boente-Carrera M; Andrews CD; McManus J; Grasperge BF; Gettie A; Coelho-dos-Reis JG; Li X; Wu D; Bruder JT; Sedegah M; Patterson N; Richie TL; Wong CH; Ho DD; Vasan S; Tsuji M
PLoS One; 2013; 8(10):e78407. PubMed ID: 24205224
[TBL] [Abstract][Full Text] [Related]
15. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
[TBL] [Abstract][Full Text] [Related]
16. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.
Goodman AL; Epp C; Moss D; Holder AA; Wilson JM; Gao GP; Long CA; Remarque EJ; Thomas AW; Ammendola V; Colloca S; Dicks MD; Biswas S; Seibel D; van Duivenvoorde LM; Gilbert SC; Hill AV; Draper SJ
Infect Immun; 2010 Nov; 78(11):4601-12. PubMed ID: 20713623
[TBL] [Abstract][Full Text] [Related]
17. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
[TBL] [Abstract][Full Text] [Related]
18. Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts.
Hui G; Choe D; Hashimoto C
Clin Vaccine Immunol; 2008 Aug; 15(8):1145-50. PubMed ID: 18562564
[TBL] [Abstract][Full Text] [Related]
19. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor.
Kumar S; Villinger F; Oakley M; Aguiar JC; Jones TR; Hedstrom RC; Gowda K; Chute J; Stowers A; Kaslow DC; Thomas EK; Tine J; Klinman D; Hoffman SL; Weiss WW
Immunol Lett; 2002 Apr; 81(1):13-24. PubMed ID: 11841841
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
